Breaking News, Collaborations & Alliances

AZ, MAP Collaborate on Asthma

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca and MAP Pharmaceuticals have formed an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP Pharmaceuticals’ proprietary nebulized formulation of budesonide. UDB is being developed by MAP Pharmaceuticals as a potential treatment for pediatric asthma and is currently in Phase III. UDB has the potential to be nebulized more quickly and at a lower nominal dose than the commercially available product. AZ will pay MAP an upfront cash payment of $40...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters